EGFR and non-small cell lung carcinoma: Accordingly, the Hsp90-inhibitor luminespib has recently shown inhibitory activity against NSCLC cells with different EGFR exon 20ins and OR in a patient with LAC carrying an exon 20ins resistant to EGFR-TKI treatment [105].